Elevated HbA1c is not associated with recurrent venous thromboembolism in the elderly, but with all-cause mortality- the SWEETCO 65+ study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
received:
13
12
2018
accepted:
21
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
The association of glycated hemoglobin (HbA1c) with venous thromboembolism (VTE) and death in the elderly is unknown. In the SWEETCO 65+ study we analyzed prospectively a Swiss Cohort of Elderly Patients with Venous Thromboembolism (SWITCO 65+). 888 patients were enrolled for the SWEETCO 65+ analysis. HbA1c was determined at baseline and divided into three categories (HbA1c < 5.7%, normal range; 5.7-6.49%, pre-diabetic range; and >6.5%, diabetic range). Median follow-up was 2.5 years. The primary endpoint was recurrent VTE. Secondary endpoints included all-cause mortality and major bleeds. The total prevalence of diabetes was 22.1%. The risk of recurrent VTE was similar in patients with HbA1c with pre-diabetes (adjusted subhazard ratio (aSHR) 1.07 [0.70 to 1.63]) and diabetes (aSHR 0.73 [0.39 to 1.37]) as compared to those with a HbA1c in the normal range. However, a HbA1c ≥ 6.5% (median IQ range 7.0 [6.70;7.60]) was significantly associated with a higher risk of all-cause mortality (adjusted hazard ratio [aHR] 1.83 [1.21 to 2.75]). In summary we found no association between HbA1c and major bleeding. Elevated HbA1c levels are not associated with recurrent VTE but with increased all-cause mortality in an elderly population with acute VTE.
Identifiants
pubmed: 32051462
doi: 10.1038/s41598-020-59173-2
pii: 10.1038/s41598-020-59173-2
pmc: PMC7016100
doi:
Substances chimiques
Biomarkers
0
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2495Références
Mozaffarian, D. et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 133, e38–360, https://doi.org/10.1161/cir.0000000000000350 (2016).
doi: 10.1161/cir.0000000000000350
pubmed: 26673558
Prandoni, P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92, 199–205 (2007).
doi: 10.3324/haematol.10516
Kearon, C. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 149, 315–352, https://doi.org/10.1016/j.chest.2015.11.026 (2016).
doi: 10.1016/j.chest.2015.11.026
pubmed: 26867832
Ruppert, A., Steinle, T. & Lees, M. Economic burden of venous thromboembolism: a systematic review. Journal of Medical Economics 14, 65–74, https://doi.org/10.3111/13696998.2010.546465 (2011).
doi: 10.3111/13696998.2010.546465
pubmed: 21222564
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C. & Schulman, S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 287s–310s, https://doi.org/10.1378/chest.126.3_suppl.287S (2004).
doi: 10.1378/chest.126.3_suppl.287S
pubmed: 15383476
Sorensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A. & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (London, England) 370, 1773–1779, https://doi.org/10.1016/s0140-6736(07)61745-0 (2007).
doi: 10.1016/s0140-6736(07)61745-0
Becattini, C. et al. A prospective study on cardiovascular events after acute pulmonary embolism. European Heart Journal 26, 77–83, https://doi.org/10.1093/eurheartj/ehi018 (2005).
doi: 10.1093/eurheartj/ehi018
pubmed: 15615803
Prandoni, P. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J. Thromb. Haemost. 4, 1891–1896, https://doi.org/10.1111/j.1538-7836.2006.02058.x (2006).
doi: 10.1111/j.1538-7836.2006.02058.x
pubmed: 16961597
Ageno, W., Becattini, C., Brighton, T., Selby, R. & Kamphuisen, P. W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117, 93–102, https://doi.org/10.1161/circulationaha.107.709204 (2008).
doi: 10.1161/circulationaha.107.709204
pubmed: 18086925
Piazza, G. & Goldhaber, S. Z. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 121, 2146–2150, https://doi.org/10.1161/circulationaha.110.951236 (2010).
doi: 10.1161/circulationaha.110.951236
pubmed: 20479165
Mi, Y., Yan, S., Lu, Y., Liang, Y. & Li, C. Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine 95, e4495, https://doi.org/10.1097/md.0000000000004495 (2016).
doi: 10.1097/md.0000000000004495
pubmed: 27512866
pmcid: 4985321
Sundell, I. B., Nilsson, T. K., Ranby, M., Hallmans, G. & Hellsten, G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. Journal of Clinical Epidemiology 42, 719–723 (1989).
doi: 10.1016/0895-4356(89)90067-X
Landin, K. et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism: Clinical and Experimental 39, 1044–1048 (1990).
doi: 10.1016/0026-0495(90)90164-8
Colwell, J. A. & Nesto, R. W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26, 2181–2188, https://doi.org/10.2337/diacare.26.7.2181 (2003).
doi: 10.2337/diacare.26.7.2181
pubmed: 12832332
Vinik, A. I., Erbas, T., Park, T. S., Nolan, R. & Pittenger, G. L. Platelet dysfunction in type 2 diabetes. Diabetes Care 24, 1476–1485, https://doi.org/10.2337/diacare.24.8.1476 (2001).
doi: 10.2337/diacare.24.8.1476
pubmed: 11473089
Ferroni, P., Basili, S., Falco, A. & Davi, G. Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2, 1282–1291, https://doi.org/10.1111/j.1538-7836.2004.00836.x (2004).
doi: 10.1111/j.1538-7836.2004.00836.x
pubmed: 15304032
Yudkin, J. S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 22(Suppl 3), C25–30 (1999).
pubmed: 10189559
Sakkinen, P. A., Wahl, P., Cushman, M., Lewis, M. R. & Tracy, R. P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology 152, 897–907, https://doi.org/10.1093/aje/152.10.897 (2000).
doi: 10.1093/aje/152.10.897
pubmed: 11092431
Duncan, B. B. et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults–the ARIC study. Atherosclerosis Risk in Communities. Obesity Research 8, 279–286, https://doi.org/10.1038/oby.2000.33 (2000).
doi: 10.1038/oby.2000.33
pubmed: 10933303
Doggen, C. J. et al. Serum lipid levels and the risk of venous thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 24, 1970–1975, https://doi.org/10.1161/01.atv.0000143134.87051.46 (2004).
doi: 10.1161/01.atv.0000143134.87051.46
pubmed: 15331431
Englyst, N. A., Taube, J. M., Aitman, T. J., Baglin, T. P. & Byrne, C. D. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 52, 1248–1255, https://doi.org/10.2337/diabetes.52.5.1248 (2003).
doi: 10.2337/diabetes.52.5.1248
pubmed: 12716760
Tracy, R. P. et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 17, 2167–2176 (1997).
doi: 10.1161/01.ATV.17.10.2167
Bermudez, E. A., Rifai, N., Buring, J. E., Manson, J. E. & Ridker, P. M. Relation between markers of systemic vascular inflammation and smoking in women. The American Journal of Cardiology 89, 1117–1119 (2002).
doi: 10.1016/S0002-9149(02)02284-1
Mendall, M. A. et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (British Cardiac Society) 78, 273–277, https://doi.org/10.1136/hrt.78.3.273 (1997).
doi: 10.1136/hrt.78.3.273
Tappia, P. S., Troughton, K. L., Langley-Evans, S. C. & Grimble, R. F. Cigarette smoking influences cytokine production and antioxidant defences. Clinical Science (London, England: 1979) 88, 485–489 (1995).
doi: 10.1042/cs0880485
Glantz, S. A. & Parmley, W. W. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 83, 1–12 (1991).
doi: 10.1161/01.CIR.83.1.1
Smith, C. J. & Fischer, T. H. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis 158, 257–267 (2001).
doi: 10.1016/S0021-9150(01)00570-6
Powell, J. T. Vascular damage from smoking: disease mechanisms at the arterial wall. Vascular Medicine (London, England) 3, 21–28, https://doi.org/10.1177/1358836x9800300105 (1998).
doi: 10.1177/1358836x9800300105
Fejes, Z. et al. Hyperglycemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thrombosis and Haemostasis, https://doi.org/10.1160/th16-04-0322 (2016).
doi: 10.1160/TH16-04-0322
Santilli, F. et al. Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thrombosis and Haemostasis 116, 1089–1099, https://doi.org/10.1160/th16-06-0471 (2016).
doi: 10.1160/th16-06-0471
pubmed: 27709225
Neergaard-Petersen, S. et al. The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. PLoS One 10, e0132629, https://doi.org/10.1371/journal.pone.0132629 (2015).
doi: 10.1371/journal.pone.0132629
pubmed: 26148094
pmcid: 4493028
Carmassi, F. et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thrombosis Research 67, 643–654 (1992).
doi: 10.1016/0049-3848(92)90068-L
Verkleij, C. J. et al. The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 17, E57–63, https://doi.org/10.1177/1076029610384112 (2011).
doi: 10.1177/1076029610384112
Stegenga, M. E. et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55, 1807–1812, https://doi.org/10.2337/db05-1543 (2006).
doi: 10.2337/db05-1543
pubmed: 16731846
Takada, Y. et al. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thrombosis Research 71, 405–415 (1993).
doi: 10.1016/0049-3848(93)90165-K
Bai, J. et al. Diabetes is associated with increased risk of venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research 135, 90–95, https://doi.org/10.1016/j.thromres.2014.11.003 (2015).
doi: 10.1016/j.thromres.2014.11.003
pubmed: 25434631
Bell, E. J. et al. Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 111, 10–18, https://doi.org/10.1016/j.diabres.2015.10.019 (2016).
doi: 10.1016/j.diabres.2015.10.019
pubmed: 26612139
Gariani, K., Mavrakanas, T., Combescure, C., Perrier, A. & Marti, C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. European Journal of Internal Medicine 28, 52–58, https://doi.org/10.1016/j.ejim.2015.10.001 (2016).
doi: 10.1016/j.ejim.2015.10.001
pubmed: 26507303
Ren, W., Li, Z., Fu, Z. & Fu, Q. Analysis of risk factors for recurrence of deep venous thrombosis in lower extremities. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 20, 199–204, https://doi.org/10.12659/msm.889819 (2014).
doi: 10.12659/msm.889819
Piazza, G. et al. Venous thromboembolism in patients with diabetes mellitus. The American Journal of Medicine 125, 709–716, https://doi.org/10.1016/j.amjmed.2011.12.004 (2012).
doi: 10.1016/j.amjmed.2011.12.004
pubmed: 22560173
pmcid: 3424058
Koenig, R. J., Peterson, C. M., Kilo, C., Cerami, A. & Williamson, J. R. Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes 25, 230–232 (1976).
doi: 10.2337/diab.25.3.230
Koenig, R. J. et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. The New England Journal of Medicine 295, 417–420, https://doi.org/10.1056/nejm197608192950804 (1976).
doi: 10.1056/nejm197608192950804
pubmed: 934240
Gabbay, K. H. et al. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 44, 859–864, https://doi.org/10.1210/jcem-44-5-859 (1977).
doi: 10.1210/jcem-44-5-859
pubmed: 858776
Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical Research ed.) 321, 405–412 (2000).
doi: 10.1136/bmj.321.7258.405
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 359, 1577–1589, https://doi.org/10.1056/NEJMoa0806470 (2008).
doi: 10.1056/NEJMoa0806470
pubmed: 18784090
Gaede, P., Lund-Andersen, H., Parving, H. H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. The New England Journal of Medicine 358, 580–591, https://doi.org/10.1056/NEJMoa0706245 (2008).
doi: 10.1056/NEJMoa0706245
pubmed: 18256393
Mean, M. et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. Journal of Thrombosis and Thrombolysis 36, 475–483, https://doi.org/10.1007/s11239-013-0875-2 (2013).
doi: 10.1007/s11239-013-0875-2
pubmed: 23359097
Little, R. R., Rohlfing, C. L. & Sacks, D. B. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clinical Chemistry 57, 205–214, https://doi.org/10.1373/clinchem.2010.148841 (2011).
doi: 10.1373/clinchem.2010.148841
pubmed: 21148304
In Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation (World Health Organization Copyright (c) World Health Organization, 2011).
Association, A. D. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 33, 62–69 (2010).
doi: 10.2337/dc10-S062
Ryden, L. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal 34, 3035–3087, https://doi.org/10.1093/eurheartj/eht108 (2013).
doi: 10.1093/eurheartj/eht108
pubmed: 23996285
Schulman, S. & Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692–694, https://doi.org/10.1111/j.1538-7836.2005.01204.x (2005).
doi: 10.1111/j.1538-7836.2005.01204.x
pubmed: 15842354
Jakobsson, C. et al. Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism. J. Thromb. Haemost. 8, 1242–1247, https://doi.org/10.1111/j.1538-7836.2010.03836.x (2010).
doi: 10.1111/j.1538-7836.2010.03836.x
pubmed: 20230422
Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94, 496–509 (1999).
doi: 10.1080/01621459.1999.10474144
Reiner, M. F. et al. Omega-3 fatty acids predict recurrent venous thromboembolism or total mortality in elderly patients with acute venous thromboembolism. J. Thromb. Haemost. 15, 47–56, https://doi.org/10.1111/jth.13553 (2017).
doi: 10.1111/jth.13553
pubmed: 27790827
Yudkin, J. S. et al. for the HOPE investigators (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48:1749–1755. Diabetologia 49, 611–612; author reply 613–614, https://doi.org/10.1007/s00125-005-0115-1 (2006).
doi: 10.1007/s00125-005-0115-1
Khaw, K. T. et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of Internal Medicine 141, 413–420 (2004).
doi: 10.7326/0003-4819-141-6-200409210-00006
Nichols, G. A., Joshua-Gotlib, S. & Parasuraman, S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. Journal of the American College of Cardiology 62, 121–127, https://doi.org/10.1016/j.jacc.2013.04.031 (2013).
doi: 10.1016/j.jacc.2013.04.031
pubmed: 23665365
Selvin, E. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. The New England Journal of Medicine 362, 800–811, https://doi.org/10.1056/NEJMoa0908359 (2010).
doi: 10.1056/NEJMoa0908359
pubmed: 20200384
pmcid: 2872990
Li, W. et al. HbA1c and all-cause mortality risk among patients with type 2 diabetes. International Journal of Cardiology 202, 490–496, https://doi.org/10.1016/j.ijcard.2015.09.070 (2016).
doi: 10.1016/j.ijcard.2015.09.070
pubmed: 26440458
Rana, O. et al. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation 124, 1548–1556, https://doi.org/10.1161/circulationaha.110.992297 (2011).
doi: 10.1161/circulationaha.110.992297
pubmed: 21911786
Gruden, G. et al. QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care 35, 125–127, https://doi.org/10.2337/dc11-1739 (2012).
doi: 10.2337/dc11-1739
pubmed: 22124713
Firmann, M. et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 8, 6, https://doi.org/10.1186/1471-2261-8-6 (2008).
doi: 10.1186/1471-2261-8-6
pubmed: 18366642
pmcid: 2311269
Rathmann, W. et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46, 182–189, https://doi.org/10.1007/s00125-002-1025-0 (2003).
doi: 10.1007/s00125-002-1025-0
pubmed: 12627316
Atlanta, G. C. F. D. C. A. P. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States (2011).
Dagogo-Jack, S. Pitfalls in the use of HbA(1)(c) as a diagnostic test: the ethnic conundrum. Nature reviews. Endocrinology 6, 589–593, https://doi.org/10.1038/nrendo.2010.126 (2010).
doi: 10.1038/nrendo.2010.126
pubmed: 20680035
Pani, L. N. et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care 31, 1991–1996, https://doi.org/10.2337/dc08-0577 (2008).
doi: 10.2337/dc08-0577
pubmed: 18628569
pmcid: 2551641